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Introduction
Antibodies against glutamic acid decarboxylase (GAD), the rate-limit-
ing enzyme involved in γ-aminobutyric acid (GABA) synthesis, are associ-
ated with several neurological disorders, including Stiff  Person Syndrome 
(SPS), epilepsy, myasthenia gravis, limbic encephalitis and cerebellar 
ataxia.1,2 However, concurrent presentation of  SPS, cerebellar ataxia and 
positive anti-GAD antibodies has only been reported in a limited number 
of  cases previously.3–5 Here, we describe such a case which demonstrates 
(1) this rare combination of  clinical features, including SPS and cerebellar 
ataxia, with limb and bulbar features; (2) symptom resistance, most nota-
bly the cerebellar ataxia, to multiple immunomodulatory therapies; and 
(3) development of  further autoimmune sequelae, namely, insulin- 
dependent diabetes, following treatment with high-dose steroids. Figure 1 
summarises symptom progression, treatment and anti-GAD titres over a 
12-year period. The patient discussed has provided written informed con-
sent for the publication of  this report.
Case description
The patient first presented at the age of  50 years, with a 9-month his-
tory of  intermittent right lower limb stiffness, described by the patient as 
‘spasms’. She described an inability to use her right foot on the brake 
pedal of  her car and had difficulty placing her right heel on the ground. 
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Abstract
Background: Antibodies against glutamic acid decarboxylase (GAD) are associated with Stiff  Person Syndrome (SPS).
Case report: A 50-year-old woman presented with symptoms progressed over 9 years, resulting in a cerebellar ataxia and right upper limb tremor. Investigations 
revealed elevated serum and CSF anti-GAD antibody titres (98.6 and 53.4 µ/ml, respectively). Treatment included intravenous immunoglobulin and immunomod-
ulation (infliximab and rituximab), improving her stiffness, but with no impact on the ataxia-related symptoms. Subsequent high-dose steroids led to diabetic keto-
acidosis and unmasking of  an insulin-dependent diabetes mellitus.
Discussion: This case illustrates several key features: (1) the combined clinical picture of  SPS and cerebellar ataxia is a rare phenotype associated with anti-GAD 
antibodies; (2) the cerebellar ataxia described was progressive and poorly responsive to immunomodulatory therapy; and (3) the potential for development of  further 
autoimmune sequelae in response to immunosuppression, namely, the development of  insulin-dependent diabetes in response to treatment with high-dose oral 
steroids.
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There was no previous medical or medication history. There was a 
strong family history of  thyroid disease (brother, mother, two maternal 
aunts, maternal grandmother) and adult-onset diabetes mellitus (DM) 
(mother and father). She had involuntary contraction of  the right lower 
limb muscles with the right foot held in plantar flexion. The remainder 
of  the neurological examination was normal. Serum, imaging and neu-
rophysiological investigations were unremarkable, with the exception 
of  strongly positive anti-GAD antibodies in both serum and CSF 
at 98.6 µ/ml (normal range: 0–5 µ/ml) and 53.4 µ/ml (positive), 
respectively. She underwent two courses of  intravenous immunoglobu-
lin (IVIg) treatment (2 g/kg) over two consecutive months with complete 
symptom resolution.
Four years later her symptoms returned with additional balance diffi-
culties and recurrent falls. She reported no autonomic or sensory symp-
toms, and cognition was normal. These symptoms progressed over the 
subsequent year limiting activities of  daily living. Clinical examination 
at this time demonstrated ongoing involuntary stiffness of  the right side, 
but no overt clinical signs of  ataxia. Ten further courses of  IVIg over the 
subsequent 2 years provided only temporary functional improvement to 
her symptoms of  stiffness, lasting 6–8 weeks at a time, with further 
symptom progression, including dysarthria, dysphagia for liquids, right 
upper limb weakness and tremor. Examination at this time (5 years after 
initial presentations) revealed dysarthria, increased right-sided limb 
tone, mild right upper limb weakness, rigidity and hypertrophy of  the 
paraspinal muscles. Repeat serum anti-GAD antibody titres were ele-
vated at >2,000 µ/ml (0–5 µ/ml) (5 years post-initial presentation; 
Figure 1); all other serum and CSF investigations, including serum cop-
per, ataxia genetics screen, anti-tissue transglutaminase (TTG), -Caspr, 
-Lgi1, -Purkinje cell, -Hu, -Yo and -Ri antibodies, were negative or 
within normal limits. CSF anti-GAD antibody titres were not repeated 
after their initial measurement at presentation (53.4 µ/ml, 2002; 
Figure 1). Treatment with IV methylprednisolone (500 mg/day for 
5 days) and plasma exchange (3 cycles in 5 days) provided no objective 
improvement.
Eight years after her initial presentation, the patient reported 
increased difficulties with balance, swallowing and blurred vision. 
Clinical examination at this point revealed dysarthria, increased right-
sided limb tone, with moderate finger to nose ataxia (right-side only) 
and dysdiadochokinesia. Examination of  her eye movements demon-
strated square wave jerks in the primary position, broken smooth pur-
suit movements and rotatory nystagmus at the extremes of  gaze. There 
was evidence of  paraspinal muscle spasm, rigidity and hypertrophy. 
She was able to walk unaided with circumduction and stiffness of  the 
right leg.
The patient’s symptoms continued to progress, and 9 years after 
symptom onset, there was evidence of  impaired horizontal saccades, 
gaze-evoked nystagmus, dysarthria, immobility and a right-side pre-
dominant, upper limb cerebellar ataxia with evidence of  dysmetria and 
intention tremor (Videos 1, 2 and 3). In spite of  a course of  immuno-
modulatory treatment (two infusions of  infliximab and a single dose of  
rituximab), her symptoms continued to deteriorate with no functional 
use of  the right hand and limited mobility. Examination at this time 
demonstrated broken-down smooth pursuit movements with gaze 
evoked nystagmus and mild dysarthria. She had moderate-to-severe fin-
ger to nose ataxia on the right, alongside mild alternating movement 
ataxia. Finger-to-nose movement and rapid alternating movements 
were normal on the left. There was moderate heel-knee-shin ataxia and 
ongoing paraspinal muscle spasm. Drawing a spiral demonstrated 
Figure 1. Schematic Timeline of  the Clinical Progression of  Symptoms, Investigations and Treatment Received over a 12-Year Period. X-axis, 
progression of  years; Blue boxes, progression of  symptoms; Purple boxes, trend of  antibody titres; Green boxes, treatment given; anti-GAD, anti-glutamic acid  decarboxylase; 
IVIg, intravenous immunoglobulin.
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unsteadiness on the right, but was normal on the left. Oral prednisolone 
(80 mg/day) was commenced, but she rapidly developed pneumonia 
and diabetic ketoacidosis (DKA) having had no previous diabetic symp-
toms. She was admitted to critical care for the management of  sepsis, 
DKA and respiratory failure and commenced on regular insulin 
following recovery. Anti-GAD antibody titres remained elevated 
(>2,000 µ/ml), and treatment was focused on symptom optimisation 
with diazepam, baclofen and amitriptyline.
Video 1. Demonstrates Intention Tremor and Past-Pointing with Finger-Nose Testing in the Right Upper Limb. The video were undertaken at the 
same time point (2012), 10 years following symptom onset (Figure 1).
Video 2. Demonstrates Slowed and Hypometric Right Horizontal Saccades. The video were undertaken at the same time point (2012), 10 years following 
symptom onset (Figure 1).
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Discussion
This case illustrates some of  the systemic features of  disease associated 
with GAD auto-antibodies, which are more typically associated with the 
destruction of  pancreatic islet beta cells in autoimmune type 1 diabetes.6 
Interestingly, in spite of  >45 case reports and case series describing cohorts 
of  individuals with features of  SPS and raised anti-GAD titres,7 the con-
stellation of  symptoms described in this case, namely, the combination of  
SPS and insidious-onset but progressive cerebellar ataxia, remains rarely 
reported. This potentially indicates a sub-group, or more severe pheno-
type, of  this disorder that warrants further, independent investigation.
Another key feature of  this case is the differential response of  the distinct 
symptom groups to immunomodulatory therapy. Initial treatment with 
IVIg proved successful in improving the SPS symptoms, maintaining good 
symptom control for more than 4 years. However, with subsequent onset of  
the cerebellar ataxia, neither more frequent treatment with IVIg nor escala-
tion of  immunomodulatory treatment (including steroids, plasma exchange 
and Rituximab) provided symptomatic relief. Hence, 5 years after symptom 
onset and an initial good response to treatment, this patient effectively devel-
oped a “treatment resistance” to all available forms of  immunosuppression, 
with an ongoing worsening of  her clinical signs and symptoms.
Finally, attempts at treatment escalation with further immunosup-
pressive therapies ultimately resulted in the development of  additional 
autoimmune sequelae. While development of  DM following steroid 
treatment is widely recognised, the importance of  GAD function in 
pancreatic islet beta cells potentially makes this patient group more vul-
nerable to the serious potential side effects of  immunosuppressive and 
immunomodulatory therapy. This emphasises the importance of  patient 
information and education regarding the potential side effects of  ther-
apy before embarking on a treatment programme, and to advise seeking 
prompt medical advice in the case of  illness.
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Video 3. Demonstrates Dysarthria with Staccato Speech. The video were undertaken at the same time point (2012), 10 years following symptom onset (Figure 1).
